SK pharmteco and Cryoport Partner on Cell and Gene Therapies
Biotechnology and pharma industries will receive logistics and manufacturing services from the two organizations
Cryoport, a supply-chain service company, and SK pharmteco, a contract development and manufacturing organization, announced on Sept. 25, 2024, that they are partnering to offer combined logistics and manufacturing services to bio/pharmaceutical companies. Cryoport will assist SK pharmteco by offering comprehensive cell and gene therapy services, which encompass biomaterial collection, shipping systems, data solutions, and bioservices.
“We are excited to be chosen by SK pharmteco to assist in the production of APIs and intermediates, biopharmaceuticals, and cell and gene therapies,” stated Jerrell Shelton, CEO of Cryoport, in a press release (1). “Our organizations work together to support the life sciences by assisting in delivering lifesaving treatments to patients. This partnership helps us connect with more individuals who need assistance and fits well with Cryoport’s plan to broaden and improve our income sources, especially as we aim to increase revenue from supporting commercial cell and gene therapies.
Dana Cipriano, vice president of Analytical Services for SK pharmteco, stated, “The cell and gene therapy industry is experiencing significant growth, and it is crucial to maintain the safety and integrity of the supply chain for these products.” We focus on our clients, and our partnership with Cryoport shows our promise to deliver top-notch services that are designed to fit the needs of our customers and the patients they support.
In April 2024, SK pharmteco made an agreement with Ferring Pharmaceuticals to offer increased manufacturing capacity for the gene therapy Adstiladrin (nadofaragene firadenovec-vncg), ensuring a steady supply of the treatment for bladder cancer.
“SK pharmteco is excited to work with Ferring Pharmaceuticals as a manufacturer of the innovative gene therapy Adstiladrin,” stated Joerg Ahlgrimm, chief executive officer of SK pharmteco, in a press release at the time of the announcement (2). “We offer a straightforward method that combines flexible clinical and commercial manufacturing solutions with thorough testing, quality control, and lot release programs. This ensures we support our partners effectively throughout their product journey, aligning perfectly with our goal of speeding up the delivery of potentially life-saving therapies to patients worldwide.”
In other company news, SK pharmteco’s facility in Swords, Ireland marked its 60th anniversary in August 2024. In 2018, SK biotek acquired the Swords facility, making it the first Korean company to establish a presence in Ireland.
“We are proud to celebrate 60 years of our Swords facility,” said Joyce Fitzharris, President of SK pharmteco Small Molecule, Europe, and leader of the Swords facility, in the press release. “This achievement reflects the strong commitment of our team, who have continually pushed for innovation and excellence.” We are dedicated to changing lives by creating therapies that make a difference, and this anniversary highlights our progress along the way.
Source: SK pharmteco
